<DOC>
	<DOCNO>NCT00693056</DOCNO>
	<brief_summary>The primary objective Phase IIa trial determine effective dos treatment period upcoming RX-10100 Phase IIb trial subject erectile dysfunction ( ED ) . The secondary objective trial evaluate safety quality life subject ED receive RX-10100 treatment .</brief_summary>
	<brief_title>Efficacy Study RX-10100 Treat Erectile Dysfunction ( ED )</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>Have ED least six month Stable , heterosexual relationship least 3 month Make least one attempt sexual intercourse per week untreated , 2week screening period At least 50 % attempt sexual intercourse untreated baseline period must unsuccessful 'Moderate ' 'mild moderate ' ED , define IIEFEF domain score 11 21 measure Following previous current medical condition Any unstable medical , psychiatric , substance abuse disorder Penile anatomical abnormality Primary hypoactive sexual desire Spinal cord injury Hypogonadism Surgical prostatectomy Stable unstable angina pectoris Myocardial infarction , stroke , lifethreatening arrhythmia Uncontrolled atrial fibrillation/flutter screen Severe chronic acute liver disease Moderate severe hepatic impairment Clinically significant chronic hematological disease Bleeding disorder Significant active peptic ulcer disease Resting hypotension hypertension Malignancy ( cancer ) NYHA Class II IV heart failures Positive test Hepatitis B surface antigen ( HBsAg ) Hepatitis C Symptomatic postural hypotension Following concomitant medication Androgens estrogens Antiandrogens Potent inhibitor cytochrome P450 3A4 Any investigational drug within 30 day Visit 1 Any treatment ED within 7 day Visit 1 study Antibiotics penicillin class Following abnormal laboratory value Serum total testosterone level ( least 25 % low ) Serum creatinine ( &gt; 3.0 mg/dl ) Elevation AST and/or ALT ( &gt; 3 time upper limit normal ) Diabetic subject HbAlc ( &gt; 6.5 % ) Subjects know hypersensitivity amoxicillin Subjects history unresponsiveness PDE5 Inhibitor treatment history significant side effect lead treatment discontinuation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Erectile Dysfunctions</keyword>
	<keyword>ED</keyword>
</DOC>